U.S. Stock Market Midday Update

Vogenx rose 19.75%, reaching a new 60-day high. Based on recent key news:

1. On August 18, Vogenx successfully completed an initial public offering (IPO) raising $81.3 million, with JonesTrading serving as the sole bookrunner. This successful IPO brought significant market attention, driving the stock price up.

2. On August 17, JonesTrading, as a leader in global block trading, provided strong liquidity support for Vogenx. This support enhanced investor confidence, further pushing the stock price higher. Market liquidity increased, and investor confidence improved.

Stocks with High Trading Volume in the Industry

Merck rose 10.64%, reaching a new 52-week high. Based on recent key news:

1. On August 19, Merck and Moderna jointly announced positive results from their personalized mRNA cancer vaccine in Phase III clinical trials, significantly reducing the risk of melanoma recurrence, which drove the stock price up. Source: MarketWatch

2. On August 19, Merck's stock price hit an all-time high due to the successful vaccine trial in collaboration with Moderna, enhancing market expectations for its future growth. Source: Benzinga

3. On August 19, Merck's second-quarter revenue grew 5% year-over-year, exceeding market expectations, further supporting the stock price increase. Source: Zhitong Finance. Biotech stocks generally rose, but risks need attention.

Eli Lilly rose 3.20%, with a trading volume of $2.667 billion. Based on recent key news:

1. On August 17, Eli Lilly registered the Phase III clinical study of Brenipatide injection for adult depression. This marks the world's first GLP-1 class product to initiate Phase III clinical trials for depression, driving the stock price up. Source: Zhitong Finance

2. On August 17, OmniAb and Eli Lilly reached a $370 million drug development agreement involving ion channel drug discovery projects. This collaboration enhanced Eli Lilly's R&D capabilities, promoting the stock price increase. Source: Zhitong Finance

3. On August 16, Eli Lilly raised its full-year revenue forecast for 2026, expecting revenue between $85 billion and $87 billion. The market holds an optimistic view of its growth potential, driving the stock price up. Source: Zhitong Finance. Competition in the pharmaceutical industry intensifies, and patent cliff risks emerge.

Pfizer rose 3.65%. Based on recent key news:

1. On August 17, Pfizer's Lyme disease vaccine, developed in collaboration with Valneva, received EMA validation. This vaccine targets six Borrelia OspA serotypes in North America and Europe, expected to significantly enhance Pfizer's competitiveness in the vaccine market, driving the stock price up.

2. On August 17, Pfizer received FDA approval for its drug Hympavzi (marstacimab-hncq) for expanded indications in the treatment of Hemophilia A or B This approval will expand Pfizer's market share, enhance profitability, and promote stock price increases.

On August 18, analyst Bruce Berkowitz revealed that 76% of his fund Fairholme Capital is invested in Pfizer, showing strong confidence in Pfizer, further boosting market sentiment and driving up the stock price. The competition in the vaccine market is intensifying, the macroeconomic environment is stable, and capital inflows are significant.

Stocks ranked at the top of the industry by market capitalization

Johnson & Johnson rose 0.98%, with increased trading volume. Based on recent key news:

1. On August 18, Johnson & Johnson faced challenges from biosimilar competition and sluggish growth in its medical technology sector. The growth of its core innovative pharmaceuticals division is impacted by intensified biosimilar competition, leading to margin compression, while growth in the medical technology sector also shows weakness. These factors may put pressure on the stock price. Source: Public Technologies

2. On August 17, Johnson & Johnson announced the launch of its latest robotic-assisted bronchoscopy technology, Monarch™ Quest 3. The release of this technology may boost market confidence in the company's innovation capabilities, driving up the stock price. Source: Johnson & Johnson announcement

3. On August 19, internal stock sales by Johnson & Johnson executives raised market concerns. CEO Joaquin Duato sold over 123,000 shares in mid-August, and the uncertainty surrounding executive changes may negatively impact the stock price. Source: SEC Form 4 The pharmaceutical industry faces the risk of a patent cliff